Senti Biosciences (SNTI) Projected to Announce Earnings on Thursday

Senti Biosciences (NASDAQ:SNTI) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Senti Biosciences to post earnings of ($0.33) per share and revenue of $0.0150 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 12:30 PM ET.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.22. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. On average, analysts expect Senti Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Senti Biosciences Price Performance

Senti Biosciences stock opened at $0.35 on Thursday. The stock has a market capitalization of $10.81 million, a price-to-earnings ratio of -0.18 and a beta of 2.04. The business has a fifty day moving average price of $0.87 and a 200-day moving average price of $0.93. Senti Biosciences has a 1-year low of $0.34 and a 1-year high of $2.88.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Chardan Capital upped their target price on Senti Biosciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new position in shares of Senti Biosciences during the 2nd quarter worth about $1,883,000. Geode Capital Management LLC grew its position in shares of Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares during the last quarter. Citadel Advisors LLC acquired a new position in Senti Biosciences in the third quarter valued at $117,000. Virtu Financial LLC acquired a new position in Senti Biosciences in the 4th quarter valued at about $46,000. Finally, Jane Street Group LLC acquired a new position in shares of Senti Biosciences in the fourth quarter valued at approximately $40,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.